Physician profile
Godofredo B Baclig
NPI 1114010709
$2,722.88
in general payments reported to CMS, 2019-2025
16 companies · $348 in 2025
The $348 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $577 · 2020: $412 · 2021: $265 · 2022: $293 · 2023: $541 · 2024: $287 · 2025: $348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,165 · Education: $10.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,165.36 |
| Education | $10.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $706.85 | 2019-2025 | Krystexxa, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $452.38 | 2019-2024 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $327.65 | 2020-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $210.89 | 2019-2024 | |
| Kowa Pharmaceuticals America, INC. | $192.99 | 2019-2025 | Livalo, Seglentis, Zoryve |
| Lilly USA, LLC | $177.84 | 2020-2025 | Jardiance, Emgality, Zepbound |
| Novartis Pharmaceuticals Corporation | $169.58 | 2022-2023 | |
| Glaxosmithkline, LLC. | $155.77 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $88.24 | 2019 | |
| Merck Sharp & Dohme LLC | $71.55 | 2020-2021 | |
| Radius Health, INC. | $44.50 | 2019-2020 | |
| Amarin Pharma, INC. | $34.61 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.08 | 2023 | |
| Vifor Pharma, INC. | $23.40 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.18 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $19.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Godofredo Baclig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.